Abstract:Multiple sclerosis (MS) is a chronic immune-mediated disease that causes inflammation, demyelination, and axonal loss in the central nervous system (CNS). [ 1 , 2 ] The complexity of MS is influenced by a variety of environmental and genetic risk factors. [ 3 , 4 ] Progressive MS is clinically defined as the accumulation of disability independent of relapses, and it is a heterogeneous disease with 2 types, primary progressive and secondary progressive. Primary progressive MS manifests as an unremitting progression that starts at the onset of the disease, as opposed to secondary progressive MS, where the progression begins after an initial relapsing-remitting course. [ 5 ] Furthermore, the pathologic mechanisms underlying progressive MS are complex, with multiple pathways involved. [ 6 , 7 ] A study by Brown et al showed that managing the disease early using disease-modifying therapies decreases the risk of conversion to secondary progressive MS. [ 8 ] It is crucial to clarify the difference in terminology between disease "progression" and "worsening" in MS. Disease progression is a phase of MS characterized by an accrual of disability independent of relapses, whereas worsening describes any increase in disability, with or without relapses. [ 5 ]

Progressive multiple sclerosis: A bibliometric analysis